Orca Bio Cell Therapy Gets Landmark FDA Nod for New Kind of Living Medicine
Frank Vinluan / medcitynews - FDA approval of Orca Bio’s Tregzi makes it the first cell therapy based on regulatory T cells, or Tregs. Clinical trial results showed reduced risk of graft-versus-host disease, a common complication of the allogeneic stem cell transplants that are a stan…
AI Summary: Orca Bio’s off‑the‑shelf allogeneic cell therapy received FDA approval, marking a milestone for engineered living medicines. Regulators cleared the product after pivotal efficacy and manufacturing data, offering broader access to cellular therapy but spotlighting cost, supply logistics and the need for robust post‑market safety surveillance.
Related Stories
FDA approves Merck’s once‑daily two‑drug HIV pill, shaking up market / 2 months
FDA approves Travere's Filspari for rare kidney disease FSGS / 2 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 6 wks
Denali drug receives accelerated approval for rare CNS indication / 3 months
FDA again rejects Aldeyra’s dry‑eye drug for weak evidence / 3 months
Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 2 months
FDA clears first once‑weekly basal insulin for Type 2 diabetes / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Medicaid, Telemedicine, Infant Health, Supply Chain and look for the RSS link.
StackHealth Time Machine